|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | NXY-059治疗急性缺血性卒中显示文摘Background: NXY-059 is a free-radical-trapping agent that is neuroprotective in animal models of stroke. We tested whether it would reduce disability in humans after acute ischemic stroke. Methods: We conducted a randomized, double-blind, placebo-controlled trial involving 1722 patients with acute ischemic stroke who were randomly assigned to receive a 72-hour infusion of placebo or intravenous NXY-059 within 6 hours after the onset of the stroke. The primary outcome was disability at 90 days, as measured according to scores on the modified Rankin scale for disability (range, 0 to 5, with 0 indicating no residual symptoms and 5 indicating bedbound, requiring constant care). Results: Among the 1699 subjects included in the efficacy analysis, NXY-059 significantly improved the overall distribution of scores on the modified Rankin scale, as compared with placebo (P = 0.038 by the Cochran-Mantel-Haenszel test). The common odds ratio for improvement across all categories of the scale was 1.20 (95 percent confidence interval, 1.01 to 1.42). Mortality and rates of serious and nonserious adverse events were each similar in the two groups. NXY-059 did not improve neurologic functioning as measured according to the National Institutes of Health Stroke Scale (NIHSS): the difference between the two groups in the change from baseline scores was 0.1 point (95 percent confidence interval, -1.4 to 1.1; P = 0.86). Likewise, no improvement was observed according to the Barthel index (P = 0.14). In a post hoc analysis of patients who also received alteplase, NXY-059 was associated with a lower incidence of any hemorrhagic transformation (P = 0.001)and symptomatic intracranial hemorrhage (P = 0.036). Conclusions: The administration of NXY-059 within six hours after the onset of acute ischemic stroke significantly improved the primary outcome (reduced disability at 90 days), but it did not significantly improve other outcome measures, including neurologic functioning as measured by the NIHSS score. Additional research is needed to confirm whether NXY-059 is beneficial in ischemic stroke. | Lees K. R. Zivin J. A. Ashwood T. et 郭俊(译) | 2006 | 世界核心医学期刊文摘(神经病学分册)2006，2，6： | 12 |
| 2 | Effects of Intense Low-Density Lipoprotein Cholesterol Reduction in Patients With Stroke or Transient Ischemic Attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial显示文摘 | Pierre Amarenco Larry B. Goldstein Michael Szarek Henrik Sillesen Amy E. Rudolph Alfred Callahan Michael Hennerici Lisa Simunovic Justin A. Zivin K Michael A. Welch | 2007 | Stroke2007，，： | 2 |
| 3 | Higher-risk periods for suicide among VA patients receiving depression treatment: Prioritizing suicide prevention efforts显示文摘 | Marcia Valenstein Hyungjin Myra Kim Dara Ganoczy John F. McCarthy Kara Zivin Karen L. Austin Katherine Hoggatt Daniel Eisenberg John D. Piette Frederic C. Blow Mark Olfson | 2008 | Journal of Affective Disorders2008，，： | 2 |
| 4 | Quantitative localization biogenic amines in the spinal cord显示文摘 | Reid JL Saavedra JM | 1975 | Brain Res1975，99，： | 1 |
| 5 | NXY-059 for acute ischemic stroke显示文摘 | Zivin JA Ashwood T | 2006 | N Engl J Med2006，354，： | 1 |
| 6 | Hemorrhagic transformation after cerebiral ischemia:mechanisms and incidence显示文摘 | Lyden PD Zivin JA | 1993 | Cerebrovasc Brain Metiu Rev1993，5，1： | 1 |
| 7 | Atorvastatin in stroke: a review of SPARCL and subgroup analysis 显示文摘 | Huisa BN Stemer AB Zivin JA | 2010 | Vasc Health Risk Manag2010，6，： | 1 |
| 8 | Spectrum of neurological deficits in experimental CNS ischemia: a quantitive study 显示文摘 | ZIVIN J A DEGIROLAMI U HURWITS E L | 1982 | Arch Neurol1982，39，： | 1 |
| 9 | Reduction of neurological damage by a peptde segment of the amyloid beta/A4 protein precursor in a rabbit spinal cord ischemia model显示文摘 | Zivin JA Satio HT | 1994 | Exp Neurol1994，129，： | 1 |
| 10 | Factors determining therapeutic window for stroke显示文摘 | Zivin JA | 1998 | Neurology1998，50，： | 1 |
| 11 | Metalloproteinase inhibition reduces thrombolytic (tissue plasmingen activator)-induces hemorrhage after thromboembolic stroke显示文摘 | Lapchak PA Chapman DF Zivin JA | 2003 | Stroke2003，31，12： | 1 |
| 12 | Factors determining therapeutic window for stroke 显示文摘 | Zivin JA | 1998 | Neurology1998，50，： | 1 |
| 13 | Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator) - induced hemorrhage after thromboembolic stroke 显示文摘 | Lapchak PA Chapman DF Zivin JA | 2000 | Stroke2000，31，12： | 1 |
| 14 | Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator) -induced hemorrhage after thromboembolic stroke 显示文摘 | Lapchak PA Chapman DF Zivin JA | 2000 | Stroke2000，31，12： | 1 |
| 15 | Factors related to the occurenceof typical paroxysmal abnormalities in the EEG records of epi-leptic patients显示文摘 | Ajmone-Marsan C’Zivin LS | 1970 | Epilepsia1970，，： | 1 |
| 16 | A technique for the rapid diagnosis of atrial tachycardia in the electrophysiology laboratory显示文摘 | Knight BP Zivin A Souza J | 1999 | J Am Coll Cardiol1999，33，： | 1 |
| 17 | Factors determining the therapeutic window for stroke 显示文摘 | Zivin JA | 1998 | Neurology1998，50，： | 1 |
| 18 | The lipophilic multifunctional antioxidant edar- avone (radieut) improves behavior following embolie strokes in rab- bits:a combination terapy study with tissue plasminogen activator显示文摘 | Lapchak PA Zivin JA | 2009 | Exp Neuro12009，215，1： | 1 |
| 19 | Stroke therapy 显示文摘 | Zivin JA Choi DW | 1991 | Seient Amer1991，265，1： | 1 |
| 20 | Spinal cord infarction : a highly reproducible stroke model显示文摘 | Zivin JA DeGirolami U | 1980 | Stroke1980，11，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员